Avid Bioservices Inc (CDMO)

[semper]

Opportunities in Cancer Immunotherapy Throttle Up: George Zavoico of JonesTrading
Source: George S. Mack of The Life Sciences Report (6/24/15)

TLSR: George, what other companies are targeting immune checkpoints?

GZ: Phosphatidylserine (PS) is an immune checkpoint being targeted by Peregrine Pharmaceuticals Inc.'s (PPHM:NASDAQ) antibody bavituximab, which is in a Phase 3 clinical trial in non-small cell lung cancer (NSCLC). PS is now becoming recognized as an upstream checkpoint inhibitor, one of the first that triggers an immune response. In this regard, it could synergize with Yervoy, Keytruda or Opdivo. To this end, Peregrine commenced a Phase 1 trial of bavituximab combined with Yervoy in advanced melanoma, and is planning a Phase 2 trial of bavituximab combined with Opdivo for NSCLC.

http://www.thelifesciencesreport.com/pub/na/opportunities-in-cancer-immunotherapy-throttle-up-george-zavoico-of-jonestrading